ArticleMolecular neurobiology2025
Uncovering Potential Susceptibility Genes for Multiple Sclerosis-Induced Neuropathic Bladder: A Mendelian Randomization Analysis.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Despite lacking a genetic explanation for the causal link between multiple sclerosis (MS) and neuropathic bladder (NPB), our study aims to explore this causality and identify novel susceptibility genes for both phenotypes. We performed linkage disequilibrium score regression to assess SNP heritability for both phenotypes. Two-sample bidirectional Mendelian randomization (MR) analyses were conducted to evaluate causal relationships between MS and NPB. We performed pathway enrichment analysis on instrumental SNPs and applied summary-data-based MR (SMR) with protein and expression quantitative trait loci. Candidate susceptibility genes were further examined through colocalization analysis and differential expression studies. Our analyses indicate a substantial genetic contribution to both MS and NPB phenotypes. MR analysis revealed that MS progression increased NPB risk (OR = 1.126; 95% CI. 1.052-1.205; p < 0.001), with no evidence of reverse causality. Pathway analysis highlighted NIK/NF-kappaB signaling and autophagosome maturation as potentially shared mechanisms. SMR (p_FDR < 0.05) and colocalization analyses (PP.H4 > 0.75) identified NFKB1 and STAT3 as candidate susceptibility genes. Transcriptomic analyses confirmed significant differential expression of these genes (p < 0.05) between MS patients and healthy controls. Our findings established a causal relationship between MS progression and NPB risk, with NFKB1 and STAT3 emerging as promising therapeutic targets for MS-induced NPB.
Indexed as
Identifiers
40327306What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.